ArticleCornea2019
Medication Burden for Patients With Bacterial Keratitis.
Article in Cornea, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Antibiotics versus placebo for acute bacterial conjunctivitis.The Cochrane database of systematic reviews · 2023Pooled it
- Critical Evaluation of Key Elements in Manufacturing Procedures and Testing Methodologies for Ocular Anti-Infective Thin Film Inserts.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- A Mixture-of-Experts Network for Infectious Keratitis Classification Using Multimodal Slit-Lamp Images: A Multicenter Study.Translational vision science & technology · 2026Article
- Microbial Keratitis in Southern Arizona.Ophthalmic research · 2026Article
- Diagnosis of microbial keratitis using smartphone-captured images; a deep-learning model.Journal of ophthalmic inflammation and infection · 2025Article
- Infectious Keratitis in Patients Over 65: A Review on Treatment and Preserving Eyesight.Clinical interventions in aging · 2024Review
- Social Risk Factor Associations With Presenting Visual Acuity in Patients With Microbial Keratitis.JAMA ophthalmology · 2023Article
- Assessment of Direct Costs of Admission Due to Presumed Microbial Keratitis in a Tertiary Referral Hospital in Thailand: A 7-Year Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections.Pharmaceutics · 2022Article
- Comparative study on costs incurred for treatment of patients with bacterial and fungal keratitis - A retrospective analysis.Indian journal of ophthalmology · 2022Article
- Open-Source Automatic Biomarker Measurement on Slit-Lamp Photography to Estimate Visual Acuity in Microbial Keratitis.Translational vision science & technology · 2021Article
- Article
- Extraction of Active Medications and Adherence Using Natural Language Processing for Glaucoma Patients.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2021Article
- Algorithm Variability in Quantification of Epithelial Defect Size in Microbial Keratitis Images.Cornea · 2020Article
- Subbasal corneal nerve damage in patients with bacterial keratitis: in vivo confocal microscopy study.Arquivos brasileiros de oftalmologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo understand medication use and patient burden for treatment of bacterial keratitis (BK).
methodsA retrospective study was conducted examining medical records of adult patients with BK in an academic cornea practice. Data collected included medications used in the treatment of BK, dosing of medications, and the number and total duration of clinical encounters. Costs of medications were estimated using the average wholesale pharmacy price. Linear regression analysis was used to investigate associations of medication use with patient demographics and corneal culture results and reported with beta estimates (β) and 95% confidence intervals (95% CIs).
resultsForty-eight patients with BK (56% female) were studied. Patients were treated for a median of 54 days with 10 visits, 5 unique medications, 587 drops, and 7 prescriptions. The estimated median medication cost was $933 (interquartile range: $457-$1422) US dollars. Positive bacterial growth was significantly associated with more visits (β: 6.16, 95% CI: 1.75-10.6, P = 0.007), more days of treatment (β: 86.8, 95% CI: 10.8-163, P = 0.026), more prescribed medications (β: 2.86, 95% CI: 1.04-4.67, P = 0.003), and more doses of medications (β: 796, 95% CI: 818-1412, P = 0.012) compared with patients who did not undergo corneal scraping. Patients were prescribed 132 more drops of medication for every 10 years of older age (β: 132, 95% CI: 18.2-246, P = 0.024). Sex and income were not associated with medication burden or treatment length.
conclusionsOlder patients and those with positive cultures incur the most medication burden in treatment of BK. Providers should be aware of medication usage and cost burden as it may affect compliance with treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.